Net profit of FDC declined 23.60% to Rs 28.30 crore in the quarter ended December 2025 as against Rs 37.04 crore during the previous quarter ended December 2024. Sales rose 0.13% to Rs 464.71 crore in the quarter ended December 2025 as against Rs 464.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales464.71464.11 0 OPM %11.2510.05 - PBDT71.9664.53 12 PBT57.1751.18 12 NP28.3037.04 -24 Powered by Capital Market - Live News

FDC announced that the Board of Directors of the Company at its meeting held on 05 February 2026, has recommended a First Interim Dividend of Rs.5 per share (i.e.500%), subject to the approval of the shareholders.Powered by Capital Market - Live News

FDC will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live News

FDC has been granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Fluconazole Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg.Powered by Capital Market - Live News

Net profit of FDC declined 60.62% to Rs 28.37 crore in the quarter ended September 2025 as against Rs 72.04 crore during the previous quarter ended September 2024. Sales declined 7.94% to Rs 473.03 crore in the quarter ended September 2025 as against Rs 513.85 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales473.03513.85 -8 OPM %7.1513.65 - PBDT53.29103.79 -49 PBT38.0990.00 -58 NP28.3772.04 -61 Powered by Capital Market - Live News